Thermo Fisher stock holds steady ahead of earnings

Thermo Fisher Scientific (ISIN US8835561023) remains a large-cap health care tools name, with its most recent annual report showing 2025 revenue of $42.88 billion, adjusted operating margin of 23.1%, and adjusted EPS of $21.03. The stock closed at $0.00 as of 24 July 2026, but the company’s reported 2025 results still frame the investment case more clearly than a one-day price move.

Revenue and margin profile

In 2025, Thermo Fisher reported $42.88 billion in revenue, compared with $42.86 billion in 2024, a change of less than 1%. Adjusted operating margin reached 23.1% in 2025, while adjusted EPS was $21.03 for the year, both figures underscoring the company’s earnings power across its laboratory and diagnostics portfolio.

The latest annual numbers matter because they show a business that remains highly cash generative even after a year of only modest top-line growth. That combination of flat revenue and double-digit profitability is the main financial lens for Thermo Fisher stock.

What the 2025 numbers say

Thermo Fisher’s 2025 revenue mix continued to rely on its core life sciences and analytical instruments franchises, which support recurring demand from pharma, biotech, academic, and industrial customers. The company’s scale also matters in a market where operating leverage can shift quickly when volumes recover or contract.

For investors, the comparison with 2024 is the key point: revenue changed by less than $20 million year over year, but adjusted EPS still reached $21.03. That gap between modest sales growth and strong earnings reflects cost control and portfolio mix, not a booming end market.

Diagnostics still matters

Thermo Fisher’s product base spans diagnostics, laboratory equipment, and specialty services, with recurring demand coming from regulated labs and biopharma customers. In the company’s 2025 reporting, those end markets continued to provide the scale that supports margin stability and cash generation.

A representative product line is the company’s laboratory and analytical instruments franchise, which remains central to Thermo Fisher’s installed base and consumables revenue. That mix is important because recurring sales often soften the impact of lumpier capital spending cycles.

Stock level and market view

The stock line remains tied to earnings delivery and margin resilience rather than to a single product cycle. On 24 July 2026, the market value reference in this article is the company’s 2025 earnings base, with adjusted EPS of $21.03 and adjusted operating margin of 23.1% providing the clearest numerical anchor.

Thermo Fisher stock therefore reads less like a story about sudden revaluation and more like one about durable scale, steady profitability, and the gap between flat revenue and strong earnings. The 2025 figures suggest that the core question is not sales expansion alone, but how efficiently the company converts its revenue base into profit.